MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'invega'. Sat, 03 Sep 2011 02:28:49 +0100 http://www.medworm.com/index.php?rid=4545254&cid=t_110556_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FabRdHoDFKxs%2F This study gives no reason why the use of this treatment should be increased” over other drugs, said Rosenheck, a researcher at the US Department of Veterans Affairs, which funded the study, explains to the news service. “It may be effective for individual patients, but as a matter of policy, this is an expensive treatment and there’s no reason to aggressively promote it.” He noted Risperdal Consta costs about $7,000 a patient, which makes the injectable the most expensive antipsychotic and the third biggest-selling med in the J&J stable at $1.3 billion in sales last year. However, J&J is already trying to shift patients to its newer Invega Sustenna. The injectable is “yesterday’s drug,” RBC Capital Markets analyst Glenn Novarro tells Bloomberg, adding ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4545254 Thu, 03 Mar 2011 12:46:36 +0100 4545254 http://www.medworm.com/index.php?rid=4507576&cid=t_110556_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fhf6Mo6pHvdw%2F The FDA issued a safety alert today about the risks of exposure of nearly two dozen antipsychotics to newborns when the drugs are taken by women during pregnancy. Specifically, the pregnancy section of drug labeling for the entire class was updated to include info about the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns. In searching its adverse events database, the agency has, so far, identified 69 cases of neonatal EPS or withdrawal through October 29, 2008, involving all antipsychotics. The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding. And symptoms varied in severity: in some newborn... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4507576 Tue, 22 Feb 2011 23:28:04 +0100 4507576 http://www.medworm.com/index.php?rid=4495434&cid=t_110556_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FHhPYuHD5KLg%2F Actually, this particular recall was initiated on February 2, but is only now coming to light - 700,000 vials of Dermabond, a liquid wound-sealing adhesive, due to reports of discoloration and Securestrap, a new product for treating hernias that is getting yanked because of concerns that packaging is, unfortunately, not sterile. The Dermabond recall is mostly restricted to the US and replacements are available, but it is not clear what caused problems with Securestrap or when shipments will resume, a spokeswoman tells us. As you may recall - pun intended - Johnson & Johnson has suffered a remarkable string of product recalls for more than a year involving a wide range of products - over-the-counter meds, including Tylenol, Rolaids, Sudafed, Mylanta, Motrin and Benadryl, some of which ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4495434 Fri, 18 Feb 2011 13:55:30 +0100 4495434 http://www.medworm.com/index.php?rid=4482970&cid=t_110556_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FuhhbOmdXx10%2F Once again, Johnson & Johnson is suffering a quality control problem leading to a product recall. This time, the health care giant has recalled approximately 70,000 pre-filled syringes for its Invega Sustenna injectable antipsychotic in the US, while still more were yanked from other countries. The reason: a crack in the syringe barrel covered by labeling, which makes it hard to detect. A spokesman for Johnson & Johnson’s Janssen unit, which markets the med, says four lots were recalled from overseas, but was unable to say exactly how many syringes were involved. He maintained, however, that no adverse events were reported. We will update you with any further info we receive. “Theoretically, a crack in the syringe barrel could compromise the sterility of the syringe c... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4482970 Wed, 16 Feb 2011 14:13:33 +0100 4482970 http://www.medworm.com/index.php?rid=4309676&cid=t_110556_109_f&fid=38951&url=http%3A%2F%2Fcarlatpsychiatry.blogspot.com%2F2011%2F01%2Fcurrent-psychiatry-now-binging-on.html Current Psychiatry is a controlled circulation "throwaway" journal that comes to all psychiatrists free of charge. It's well-written, often useful, but editorially it has unfortunately become a mouthpiece for the promotional aims of its advertisers. Recently a few examples attracted my attention. 1. This CME Supplement was packaged with the November 2010 issue. It is called “Effective Strategies for Patients With Complex Depression in Psychiatric Practice." It's supported by AstraZeneca, maker of Seroquel, and the supplement's three articles are well-masked ads for the use of Seroquel in treatment-resistant depression. There are lots of subtle promotional strategies here, but check out especially pages 10 and 11. Here, you find a paragraph on atypicals pretending that they all have ... The Carlat Psychiatry Blog blogs http://www.medworm.com/rss/comments.php?id=4309676 Tue, 04 Jan 2011 20:13:00 +0100 4309676 http://www.medworm.com/index.php?rid=1472695&cid=t_110556_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F299264877%2F New York psychiatrist Jeff Lieberman has heard J&J’s sales pitch for its new Invega schizophrenia drug, but he’s not too impressed. The problem, he tells Dow Jones, is that Ivega isn’t much different than one of J&J’s best-selling drugs, the antipsychotic Risperdal. In late June, Risperdal is scheduled to lose patent protection, clearing the way for cheaper generics, which could further diminish Invega sales, already characterized as a disappointment by J&J. “I don’t think they have a strong case to make,” Lieberman, chairman of the psychiatry department at Columbia University’s medical school, tells the news service. “It’s basically a me-too drug, and the company hasn’t done the studies that would be required... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1472695 Tue, 27 May 2008 18:43:28 +0100 1472695 http://www.medworm.com/index.php?rid=1005173&cid=t_110556_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F180083599%2Frisperdal-er-invega-for-depression.html A new study (published in the Annals of Internal Medicine ) demonstrated that risperidone (Risperdal) was effective in reducing depressive symptoms in people who had not responded to a prior course of antidepressant treatment. But how effective? What is the marketing angle? How does this tie in with Invega? Let's find out...What is Effective? People who were not responding to their current antidepressant were assigned to receive risperidone or placebo as an add-on to their current antidepressant treatment. On average, people taking Risperdal improved by 2.8 points on the Hamilton Depression Rating Scale (HAM-D) relative to people taking placebo. Look over the scale and tell me if you think 2.8 points is a very meaningful difference. Decide for yourself. Yes, the difference was statisticall... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=1005173 Mon, 05 Nov 2007 15:10:00 +0100 1005173 http://www.medworm.com/index.php?rid=988452&cid=t_110556_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F176765077%2Fjj_submits_paliperidone_palmit.html Johnson & Johnson Pharmaceutical Research and Development has submitted paliperidone palmitate to the U.S. Federal Drug Administration for New Drug Application. Paliperidone palmitate is a once monthly antipsychotic intramuscular injection for the treatment of schizophrenia.To be marketed by Janssen L.P. upon FDA approval, the injection is a long acting injectable of the active ingredient Invega. It is estimated that 1 in 100 people develop schizophrenia, worldwide, and that over 2,000,000 people suffer from the disease in the U.S alone. The symptoms of the illness include hallucinations, delusions, depression, blunted emotions, disorganized thinking and social withdrawal.Janssen, a subsidiary of J&J, is the only pharmaceutical company in the US that is dedicated solely t... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=988452 Mon, 29 Oct 2007 17:15:19 +0100 988452 http://www.medworm.com/index.php?rid=982546&cid=t_110556_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F175415722%2Fblog-on-atypical-antipsychotics-sweet.html I have discovered a blog (simply titled Atypical Antipsychotics ) that I believe has some serious potential. It has the following things I like in a blog: SarcasmUnwillingness to blindly accept marketing department-generated BSIt disses Invega Not sure what more anyone could want in a blog, really. Only a few posts so far, but you can bet that I'll be watching it like a hawk. And I invite you to do likewise. (Source: Clinical Psychology and Psychiatry: A Closer Look) Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=982546 Fri, 26 Oct 2007 15:23:00 +0100 982546 http://www.medworm.com/index.php?rid=956076&cid=t_110556_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F170659651%2Finvega-just-in-nick-of-time.html In a Bloomberg report, it was noted that:Johnson & Johnson cut costs as it faces generic competition to its best-selling prescription drug, the antipsychotic Risperdal, which generated $4.2 billion last year. Phew, it's a good thing that Invega (Son of Risperdal) is on the market to save the day for J & J. And there is some preliminary (read: probably bogus) research suggesting that it works better than Seroquel in treating schizophrenia. See my recent post to understand my skepticism regarding the latest results. Invega is entering a crowded market (Abilify, Seroquel, Zyprexa, generic risperidone, Geodon, etc.) and I don't think it is going to fare particularly well unless there is some pretty darned impressive marketing. Which is not entirely out of the question. I humbly suggest... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=956076 Tue, 16 Oct 2007 13:46:00 +0100 956076 http://www.medworm.com/index.php?rid=952102&cid=t_110556_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F170156754%2Fson-of-risperdal-beats-seroquel.html Janssen, manufacturer of Invega (son of Risperdal) funded a study comparing Invega, Seroquel, and placebo in the treatment of schizophrenia. Results were as follows:"After two weeks, those on Invega had a greater reduction in symptoms as measured by a standard test called Positive and Negative Syndrome Scale for Schizophrenia, or Panss. The test measures symptoms such as disorganized thoughts and uncontrolled hostility. The score for Invega patients declined 23.4 points, 17.1 points for Seroquel and 15 points for placebo, according to J&J." By the way, note the rather paltry advantage of Seroquel in comparison with placebo. These results fit nicely into a pattern. A study published in the American Journal of Psychiatry in 2006 found that clearly, the best predictor of which antipsychot... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=952102 Mon, 15 Oct 2007 14:11:00 +0100 952102 http://www.medworm.com/index.php?rid=528028&cid=t_110556_109_f&fid=34730&url=http%3A%2F%2Fpsychiatrist-blog.blogspot.com%2F2007%2F04%2Ffda-drugs-december-2006.html I'm a bit behind on listing relevant FDA update info, so I'll get you all up to date.Zyprexa (olanzapine) labeling change: Label was revised to state that "Rare postmarketing reports of hepatitis have been received. Very rare cases of cholestatic or mixed liver injury have also been reported in the postmarketing period." [.pdf]Bifeprunox for Schizophrenia: Phase III results were released showing that patients did better on this than on placebo over 6 months (not hard to beat placebo). They also reported weight and lipid profile reductions. Their New Drug Application was submitted to the FDA in October.Invega (iloperidone) results: These results are interesting in that they looked at efficacy and side effects data stratified by whether or not one had a particular pharmacogenetic genotype. ... Shrink Rap blogs http://www.medworm.com/rss/comments.php?id=528028 Sat, 07 Apr 2007 15:20:00 +0100 528028